The effects of six months Persicaria minor extract supplement among older adults with mild cognitive impairment: a double-blinded, randomized, and placebo-controlled trial.
Brain-derived neurotrophic factor
Medicinal plants
Mild cognitive impairment
Mood
fMRI
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
19 Oct 2020
19 Oct 2020
Historique:
received:
29
03
2020
accepted:
20
09
2020
entrez:
20
10
2020
pubmed:
21
10
2020
medline:
24
6
2021
Statut:
epublish
Résumé
Persicaria minor extract exhibits antioxidant and anti-inflammatory properties and has potential effects on cognitive function and mood. However, the effects of P.minor on brain activation and biomarkers have not been studied among older adults. This multicentre, randomized, double-blinded, placebo-controlled study aimed to investigate the effect of 6 months P.minor extract supplement (Biokesum®) on cognition, mood, biomarkers, and brain activation among older adults with Mild Cognitive Impairment (MCI). A total of 36 Malaysian community-dwelling older adults with MCI (60-75-year-old) were randomized into Biokesum® (n = 18) and placebo group (n = 18). Each subject consumed one capsule of Biokesum® (250 mg/capsule) or placebo (maltodextrin, 280 mg/capsule) twice daily for 6 months. Cognitive function and mood were assessed at baseline, 3rd, and 6th-month using neuropsychological tests (MMSE, Digit Span, RAVLT, Digit Symbol, and Visual Reproduction) and Profile of Mood State (POMS) questionnaire. Blood lipid profile, fasting blood glucose, and biomarkers (MDA, LPO, COX-2, iNOS, and BDNF) were measured at baseline and 6th month. By the end of the intervention, there were 30 compliers (Biokesum®: N = 15; Placebo: N = 15) and 6 dropouts. For brain activation assessment, 15 subsamples (Biokesum®: N = 8; Placebo: N = 7) completed N-back and Stroop tasks during fMRI scanning at baseline and 6th month. The dorsolateral prefrontal cortex (Brodmann's area 9 and 46) was identified as a region of interest (ROI) for brain activation analysis using SPM software. Two-way mixed ANOVA analysis showed significant improvements in Visual Reproduction II (p = 0.012, partial η Six months Biokesum® supplementation potentially improved visual memory, negative mood, BDNF, and triglyceride levels among older adults with MCI. Significant findings on brain activation at the right DPLFC must be considered as preliminary. Retrospectively registered on 30th August 2019 [ ISRC TN12417552 ].
Sections du résumé
BACKGROUND
BACKGROUND
Persicaria minor extract exhibits antioxidant and anti-inflammatory properties and has potential effects on cognitive function and mood. However, the effects of P.minor on brain activation and biomarkers have not been studied among older adults. This multicentre, randomized, double-blinded, placebo-controlled study aimed to investigate the effect of 6 months P.minor extract supplement (Biokesum®) on cognition, mood, biomarkers, and brain activation among older adults with Mild Cognitive Impairment (MCI).
METHOD
METHODS
A total of 36 Malaysian community-dwelling older adults with MCI (60-75-year-old) were randomized into Biokesum® (n = 18) and placebo group (n = 18). Each subject consumed one capsule of Biokesum® (250 mg/capsule) or placebo (maltodextrin, 280 mg/capsule) twice daily for 6 months. Cognitive function and mood were assessed at baseline, 3rd, and 6th-month using neuropsychological tests (MMSE, Digit Span, RAVLT, Digit Symbol, and Visual Reproduction) and Profile of Mood State (POMS) questionnaire. Blood lipid profile, fasting blood glucose, and biomarkers (MDA, LPO, COX-2, iNOS, and BDNF) were measured at baseline and 6th month. By the end of the intervention, there were 30 compliers (Biokesum®: N = 15; Placebo: N = 15) and 6 dropouts. For brain activation assessment, 15 subsamples (Biokesum®: N = 8; Placebo: N = 7) completed N-back and Stroop tasks during fMRI scanning at baseline and 6th month. The dorsolateral prefrontal cortex (Brodmann's area 9 and 46) was identified as a region of interest (ROI) for brain activation analysis using SPM software.
RESULTS
RESULTS
Two-way mixed ANOVA analysis showed significant improvements in Visual Reproduction II (p = 0.012, partial η
CONCLUSION
CONCLUSIONS
Six months Biokesum® supplementation potentially improved visual memory, negative mood, BDNF, and triglyceride levels among older adults with MCI. Significant findings on brain activation at the right DPLFC must be considered as preliminary.
TRIAL REGISTRATION
BACKGROUND
Retrospectively registered on 30th August 2019 [ ISRC TN12417552 ].
Identifiants
pubmed: 33076878
doi: 10.1186/s12906-020-03092-2
pii: 10.1186/s12906-020-03092-2
pmc: PMC7574246
doi:
Substances chimiques
Biomarkers
0
Plant Extracts
0
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
315Subventions
Organisme : Biotropics Sdn. Bhd
ID : NN-2017-036
Références
Expert Opin Investig Drugs. 2013 Jul;22(7):863-80
pubmed: 23642183
Nutrients. 2017 Feb 05;9(2):
pubmed: 28165426
ScientificWorldJournal. 2013 Dec 29;2013:162750
pubmed: 24470791
PLoS One. 2012;7(8):e42676
pubmed: 22880079
J Neurosci. 2009 Apr 1;29(13):4056-64
pubmed: 19339601
Behav Brain Res. 2010 May 1;209(1):73-9
pubmed: 20096732
Funct Neurol. 2014 Jul-Sep;29(3):189-93
pubmed: 25473739
J Gerontol A Biol Sci Med Sci. 2016 Oct;71(10):1376-83
pubmed: 26508298
Nat Prod Commun. 2014 Sep;9(9):1345-50
pubmed: 25918808
Medicines (Basel). 2015 Sep 08;2(3):251-286
pubmed: 28930211
Biomed Pharmacother. 2019 Jan;109:1085-1099
pubmed: 30551359
Curr Alzheimer Res. 2014;11(5):484-93
pubmed: 24801219
Biomed Res Int. 2018 Jan 15;2018:4810394
pubmed: 29568754
Aging Ment Health. 2020 Sep;24(9):1514-1522
pubmed: 31046424
Curr Neuropharmacol. 2019;17(12):1158-1175
pubmed: 31400269
Cortex. 2013 May;49(5):1195-205
pubmed: 22789779
Compr Rev Food Sci Food Saf. 2018 May;17(3):714-731
pubmed: 33350133
Neurobiol Aging. 2017 Apr;52:39-52
pubmed: 28110104
Nutr Neurosci. 2019 Jan;22(1):1-18
pubmed: 28696163
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2020 Nov;27(6):918-934
pubmed: 31829793
Sci Rep. 2017 Dec 13;7(1):17548
pubmed: 29235506
Medicines (Basel). 2018 Aug 25;5(3):
pubmed: 30149600
Physiol Res. 2018 Nov 14;67(5):795-808
pubmed: 30044120
Nutr Neurosci. 2021 Nov;24(11):873-884
pubmed: 31736428
Bratisl Lek Listy. 2018;119(1):28-31
pubmed: 29405727
BMC Complement Altern Med. 2014 Sep 25;14:355
pubmed: 25252832
BMC Complement Altern Med. 2014 May 19;14:161
pubmed: 24886679
Br J Nutr. 2016 Jun;115(12):2106-13
pubmed: 27102361
Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13336-41
pubmed: 12244209
J Agric Food Chem. 2018 Jan 10;66(1):70-80
pubmed: 29249156
J Nutr Biochem. 2015 Nov;26(11):1308-16
pubmed: 26277481
Biol Psychiatry. 2012 Oct 15;72(8):700-6
pubmed: 22695185
J Int Neuropsychol Soc. 2019 Nov;25(10):1001-1010
pubmed: 31543085
Lancet. 2017 Dec 16;390(10113):2673-2734
pubmed: 28735855
J Thorac Dis. 2009 Dec;1(1):51-4
pubmed: 22263004
Science. 2006 Oct 6;314(5796):140-3
pubmed: 17023662
Evid Based Complement Alternat Med. 2013;2013:238454
pubmed: 24371452
Antioxidants (Basel). 2019 May 27;8(5):
pubmed: 31137783
Antioxidants (Basel). 2019 Jul 02;8(7):
pubmed: 31269679
Geriatr Gerontol Int. 2019 Mar;19(3):233-239
pubmed: 30618211
Clin Interv Aging. 2017 May 25;12:903-910
pubmed: 28579767
Br J Nutr. 2013 Aug 28;110(3):420-5
pubmed: 23312069
J Clin Psychiatry. 2018 Nov 27;80(1):
pubmed: 30549490
Neurology. 2005 Feb 8;64(3):501-8
pubmed: 15699382
J Toxicol Sci. 2013;38(3):459-70
pubmed: 23665944
J Clin Transl Res. 2017 Dec 03;3(3):337-343
pubmed: 30895275
Arch Toxicol. 2015 Jul;89(7):1035-44
pubmed: 25895140
Neuroimage. 2002 Dec;17(4):1820-9
pubmed: 12498755
Cardiol J. 2021;28(4):534-542
pubmed: 30912576
Asian Pac J Trop Biomed. 2014 Jun;4(6):430-5
pubmed: 25182942
Pharmacogn Mag. 2016 Jul;12(Suppl 4):S424-S430
pubmed: 27761069
Cortex. 2010 Apr;46(4):535-49
pubmed: 19674742
Appetite. 2014 Jun;77:1-12
pubmed: 24582585
J Food Drug Anal. 2017 Apr;25(2):409-416
pubmed: 28911684
J Clin Med. 2019 Oct 25;8(11):
pubmed: 31717708
Acta Pharm Sin B. 2015 Jan;5(1):47-54
pubmed: 26579424
PLoS One. 2015 Oct 08;10(10):e0139574
pubmed: 26448331